Exelixis, Inc. ( EXEL ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 9:30 AM EST
Company Participants
Andrew Peters - Senior Vice President of Strategy
Conference Call Participants
Michael Schmidt - Guggenheim Securities, LLC, Research Division
Presentation
Michael Schmidt
Guggenheim Securities, LLC, Research Division
I'm with Exelixis. With me today, I have Andrew Peters, Chief Strategy Officer. My name is Michael Schmidt, biotech analyst with Guggenheim. I'm looking really forward to this. Welcome, Andrew.
Andrew Peters
Senior Vice President of Strategy
Thank you for having me.
Question-and-Answer Session
Michael Schmidt
Guggenheim Securities, LLC, Research Division
Andrew, so Exelixis just reported solid third quarter earnings. The stock is near an all-time high. Zanza is under FDA review. How would you describe Exelixis' focus today as you bridge from cabo to the zanza franchise?
Andrew Peters
Senior Vice President of Strategy
Yes.…